Jack Warner: Arrested ex-FIFA official cites Onion article to defend himself. http://t.co/6UQxTQSrmW
5:40am June 2nd 2015 via Hootsuite
RT @PopSci: Tiny human brains, grown in a petri dish, have big implications for personalized medicine http://t.co/TrwYFLdUHV http://t.co/oF…
5:28am June 2nd 2015 via Hootsuite
RT @genetics_blog: Microbial Community Distortion after Whole-Genome Amplification http://t.co/PM9lxni5bB
5:05am June 2nd 2015 via Hootsuite in reply to genetics_blog
FBI notifies crime labs of errors used in DNA match calculations since 1999 - The Washington Post http://t.co/dCK4RR4DIQ
11:40pm June 1st 2015 via Hootsuite
RT @AACR: #AACR15 webcast: Stratton @sangerinstitute on cancer genomes & cancer development http://t.co/2OL2NitNgu http://t.co/bGvnx4Spi
9:15pm June 1st 2015 via Hootsuite
How To Use Time Travel To Increase Happiness: http://t.co/im0dEEXmbI
8:40pm June 1st 2015 via Hootsuite
Richard Thaler on misbehavior, tipping, and economists as failed mathematicians - Quartz http://t.co/wIR33xeC8H
7:25pm June 1st 2015 via Hootsuite
Sabet: Increase utility in linking ctDNA to mech of resistance, but what will it do to cost and complexity of the assay? #ASCO15
6:35pm June 1st 2015 via Hootsuite
Sabet: '13 Ascierto Break-2 study http://t.co/remuM9JZsP Need to increase sens (BEAMing, ddPCR); perh. utility in 50% cases #ASCO15
6:34pm June 1st 2015 via Hootsuite
Sabet: Abs 9017 - exosomal RNA, ctDNA combined. 12 pts w/BRAF mut melanoma. 9/12 respond, mBRAF fx decreased in 11/12. #ASCO15
6:33pm June 1st 2015 via Hootsuite
Sabet: Abs 9015: n=13 mBRAF ctDNA; 12/16 det mutation pre-Rx, 0/16 post-Rx. Sens 74%, Spec 100% #ASCO15
6:32pm June 1st 2015 via Hootsuite
Sabet: Commentary - promising early result, but choice of markers brings questions. Other Q's around monitoring, frequency, Rx #ASCO15
6:29pm June 1st 2015 via Hootsuite
Sabet: 200 papers (!) around markers: CD146 (MCAM, MUC18); HMW-MAA (CSPG4) is exp in 80% of mel; conflicted data on prognostic value #ASCO15
6:28pm June 1st 2015 via Hootsuite
Sabet: Abs 9016 Lucci used CellSearch, CD146+/HMW-MAA+/CD45-/CD34-. 10mo FU: 43/100 pts ID CMC; 28% relapse in CMC+, 7% in CMC- #ASCO15
6:25pm June 1st 2015 via Hootsuite
Sabet: Focus on circ. melanoma cells (CMCs) and ctDNA. Attractive - metastatic potential, prevalence of BRAF mutations #ASCO15
6:24pm June 1st 2015 via Hootsuite
Mohammed Kashani-Sabet (CA Pacific Med Ctr) "Usefulness of Liquid Biopsies" #ASCO15 Abs 9015-9017 'Watch this space'
6:23pm June 1st 2015 via Hootsuite
Q:How specific to melanoma? A: Looking thru TCGA of all datatypes; bladder ca beta-catenin seen. #ASCO15
6:21pm June 1st 2015 via Hootsuite
.@DrNDisis The speaker mentioned work with Steve Baylin at Hopkins on this. (She had several other ideas too - couldn't catch them all!)
6:18pm June 1st 2015 via Hootsuite in reply to DrNDisis
Ribas: Conclude: T-cell recognition of tumors, what limits infiltration, how T-cells induce responses: of high interest #ASCO15
6:15pm June 1st 2015 via Hootsuite
Ribas:Abs 9014 beta-catenin signalling prevents anti-tumor immunity by Wnt. #ASCO15 '15 Nature http://t.co/HZhMJpIicP
6:14pm June 1st 2015 via Hootsuite
Ribas:Bim+ PD-1+ CD8 T-cells decreased in 3 mos in responders (cp to non); indirect measurement #ASCO15
6:12pm June 1st 2015 via Hootsuite
Ribas: 2nd abstract (9013) - flow analysis of PBMC from 38 pts treated with pembrolizumab. CD8+ T-cells w/Bim+ above baseline #ASCO15
6:11pm June 1st 2015 via Hootsuite
Ribas: BDCA3+ APCs also more prevalent in responders. #ASCO15
6:09pm June 1st 2015 via Hootsuite
Ribas:Flow cytometry char of TIL; 25 w/ipi, 12 w/anti-PD-1; only 2 w/paired biopsies. Of anti-PD-1: responders have TILs activated #ASCO15
6:08pm June 1st 2015 via Hootsuite
Antoni Ribas (UCLA) "Biomarkers for PD1 Inhibition - Abs 9012 #ASCO15 Context from '15 Review http://t.co/qX2IpB0jWF
6:06pm June 1st 2015 via Hootsuite
Kefford: Metastatic uveal melanoma unmet need. PDL1 exp high level. 2 reports at AACR, 1 CR (liver) and 1 PR #ASCO15
5:51pm June 1st 2015 via Hootsuite
Kefford: Kluger Abs 9009: Ph2 pembrolizumab:partial remissions were small lesions. Tough area, radiation + immunotherapy #ASCO15
5:50pm June 1st 2015 via Hootsuite
Richard Kefford (Crown Princess Mary CC) "Anti-PD-1 Rx in Special Clinical Cohorts" Dabrafinib OS only 9mos Ipilimumab 26% durable #ASCO15
5:48pm June 1st 2015 via Hootsuite
Q:How much of the genome to sample for mut load? A: From 300 gene exons - can normalize to per-MB freq. POLE-e panel does well #ASCO15
5:17pm June 1st 2015 via Hootsuite
Charen: Implications: Impressive ovarian ca response http://t.co/P64eClPlNc idea - evoke pro-inflammatory state w/hypomethyl. agents #ASCO15
5:11pm June 1st 2015 via Hootsuite
Charen: Illust from '14 ref http://t.co/iy1c2ZAVBr on immune system networks #ASCO15
5:08pm June 1st 2015 via Hootsuite
Charen: BRCA1/2 have 1/10th the POLE mutations (SNVs) #ASCO15 Birkbak '13 http://t.co/O3i4RnGEjs New data '15 Nature http://t.co/uSNJZbTdlb
5:06pm June 1st 2015 via Hootsuite
Charen: '13 Cell fig http://t.co/bFy0mOprf9 of microsatellite instability landscape #ASCO15
5:04pm June 1st 2015 via Hootsuite
Charen:C->T from UV not predictive of neoantigens (for melanoma), but C-> A from smoking are better #ASCO15
5:02pm June 1st 2015 via Hootsuite
Charen: MHC-I neoantigens: predicted to be presented POLE and microsatellite instable better than the microsatellite stable ones #ASCO15
5:01pm June 1st 2015 via Hootsuite
Alexandra Charen (MSKCC) "Defining Neoantigens" #ASCO15 Will talk about mutations and predicted neoantigens.
4:59pm June 1st 2015 via Hootsuite
Strickland: HR-intact tumors may not be ideal candidates for PD-1/PD-L1 pathway inhibitors #ASCO15
4:57pm June 1st 2015 via Hootsuite
Strickland: But no difference seen on the tumor of PD-L1 of BRCA1/2-mut and HR-intact tumors #ASCO15
4:56pm June 1st 2015 via Hootsuite
Strickland: PD-L1: increased also in intratumoral and peritumoral immune cells. #ASCO15
4:55pm June 1st 2015 via Hootsuite
Stricklan: Peritumoral lyphocytes increased in BRCA mutated tumors. PD-1 exp more freq in TIL and PTLs also #ASCO15
4:54pm June 1st 2015 via Hootsuite
Strickland: Eval BRCA1/2 ov ca w/higher number of TILs, and numbers of PD-1 and PD-L-1 markers. HR-intact vs BRCA1/2 mut smples #ASCO15
4:50pm June 1st 2015 via Hootsuite
Strickland: BRCA1/2 comprise 15% of all ov ca. Overexp. results in error prone DNA repair. POLQ results in alt homology joining #ASCO15
4:48pm June 1st 2015 via Hootsuite
Kyle Strickland (Brigham and Womens) "TIL and peritumoral T cells and expression of PD -L1 in BRCA1/2-mut in hi grade serous ov ca" #ASCO15
4:47pm June 1st 2015 via Hootsuite
Brooke Howitt (Briham and Womens) "Association of POLE-mutated and MSI endometrial ca w/ higher expression of PD-L1" #ASCO15
4:38pm June 1st 2015 via Hootsuite
Daud: Median time to response was 8w. Duration PD-1 > PD-L-1. Both active in pts heavily pretreated for ovarian ca #ASCO15
4:30pm June 1st 2015 via Hootsuite
Daud: PD-1 vs PD-L-1 are both active. #ASCO15 '15 Nature Rev Immunol '15 http://t.co/ZDLXv2Cw8Z Varga results: mild AE's ORR 11%
4:29pm June 1st 2015 via Hootsuite
Daud:Shows somatic mutation plot from Alexandrov Nature '13 paper http://t.co/o2As7p6CnH Mut burden of ovarian in middle #ASCO15
4:25pm June 1st 2015 via Hootsuite
Adil Daud (UCSF) "Paddling Along with PD-L1 Research" #ASCO15
4:23pm June 1st 2015 via Hootsuite
Varga: One example of reduction shown; pt already had 4 treatments, dramatic results. Review: no mortality, no discont. b/c of AE #ASCO15
4:22pm June 1st 2015 via Hootsuite
Varga: 11.5% ORR, 1pt w/compl. resp, 2 partial. 6 stable disease (total 34%, cohort heavily pre-treated). Waterfall: 23% decreased #ASCO15
4:21pm June 1st 2015 via Hootsuite
